Ra Capital Management, L.P. - Jun 15, 2022 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Director, 10%+ Owner
Signature: /s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Stock symbol: ABOS
Transactions as of: Jun 15, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/21/2022, 04:30 PM
Previous filing: Jun 17, 2022
Next filing: Jun 21, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Stock Option (Right to Buy)	Award	$0	+25K		$0.00	25K	Jun 15, 2022	Common Stock	25K	$3.59	See footnotes	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"),RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F2	The shares subject to the option will vest on on the earlier of June 15, 2023 or the 2023 annual stockholder meeting, subject to Laura Stoppel's continuous service through each such vesting date.
F3	Laura Stoppel is a Principal of the Adivser who serves on the Issuer's board of directors. Under Ms. Stoppel's arrangement with the Adviser, Ms. Stoppel holds the option for the benefit of the Fund, the Nexus Fund II and the Account. Ms. Stoppel is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.

Remarks:

Laura Stoppel, a Principal of the Adviser, serves on the Issuer's board of directors.